SCHEMBL6237378

SCHEMBL6237378

O=c1c(Br)c(NCc2ccc(F)cc2)cnn1Cc1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.69
RAB9A P51151 2/20 0.69
MAPK14 Q16539 3/20 0.62
BRD4 O60885 3/20 0.52
KAT2B Q92831 2/20 0.52
HTT P42858 3/20 0.49
PKM P14618 2/20 0.49
MITF O75030 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
BRD9 Q9H8M2 2/20 0.48
MAPT P10636 1/20 0.44
TP53 P04637 1/20 0.43
ALDH1A1 P00352 2/20 0.42
LMNA P02545 2/20 0.42
HPGD P15428 2/20 0.42
KDM4E B2RXH2 1/20 0.42
PTGS1 P23219 1/20 0.41
PTGS2 P35354 1/20 0.41
PFKFB3 Q16875 1/20 0.41
PKLR P30613 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6232549 0.78 BPTF (0.49) SMN1; SMN2RAB9AMAPK14BRD4KAT2B
SCHEMBL6376415 0.77 MAPK14 (1.00) SMN1; SMN2RAB9AMAPK14BRD4KAT2B
SCHEMBL3985633 0.76 RAB9A (0.61) SMN1; SMN2RAB9AMAPK14HTTPKM
SCHEMBL6265589 0.76 MAPK14 (0.62) SMN1; SMN2RAB9AMAPK14HTTPKM
SCHEMBL6270038 0.75 SMN1; SMN2 (0.47) SMN1; SMN2RAB9AHTTPKMMITF
SCHEMBL4047300 0.73 ALDH1A1 (0.54) SMN1; SMN2RAB9AHTTPKMMITF
SCHEMBL6348612 0.72 MAPK14 (1.00) SMN1; SMN2RAB9AMAPK14BRD4KAT2B
SCHEMBL7822058 0.72 MAPT (0.55) SMN1; SMN2RAB9AMAPK14BRD4KAT2B
SCHEMBL6271937 0.72 ALDH1A1 (0.50) SMN1; SMN2RAB9AHTTNPSR1MAPT
SCHEMBL6604659 0.71 PFKFB3 (0.52) SMN1; SMN2HTTPKMNPSR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050256122-A1 Substituted pyridazinones PHARMACIA CORPORATION 2005-11-17 US claimed
US-20050020594-A1 Substituted pyridazinones PHARMACIA CORPORATION 2005-01-27 US claimed
US-20040142932-A1 Substituted pyridazinones PHARMACIA CORPORATION 2004-07-22 US claimed
US-20050256122-A1 Substituted pyridazinones PHARMACIA CORPORATION 2005-11-17 US disclosed
WO-2005007632-A1 SUBSTITUTED PYRIDAZINONES AS INHIBITORS OF P38 PHARMACIA CORPORATION (US) 2005-01-27 WO disclosed
US-20050020594-A1 Substituted pyridazinones PHARMACIA CORPORATION 2005-01-27 US disclosed
EP-1470112-A1 SUBSTITUTED PYRIDAZINONES AS INHIBITORS OF P38 Pharmacia Corporation (US) 2004-10-27 EP disclosed
US-20040142932-A1 Substituted pyridazinones PHARMACIA CORPORATION 2004-07-22 US disclosed
WO-2003059891-A1 SUBSTITUTED PYRIDAZINONES AS INHIBITORS OF P38 PHARMACIA CORPORATION (US) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142932-A1 Substituted pyridazinones MAP4K2, MAPK6, MAP3K6 SMN1; SMN2 1185/4885RAB9A 2668/4885MAPK14 29/4885
US-20050020594-A1 Substituted pyridazinones MAP4K2, MAPK6, MAP3K6 SMN1; SMN2 1153/4885RAB9A 2627/4885MAPK14 34/4885
US-20050256122-A1 Substituted pyridazinones MAP4K2, MAPK6, MAP3K6 SMN1; SMN2 1153/4885RAB9A 2627/4885MAPK14 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.